NEW DRUGS...
"BioMS Medical's MBP8298 shows 5-year delay of MS disease progression..." :
" MBP8298 delayed disease progression for 5 years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes. BioMS Medical Corp. also announced that treatment and follow-up of patients from a phase II clinical study demonstrated that patients in this DR2 and DR4 responder group, who comprise up to 75% of MS patients, had a median time to disease progression (worsening) of 78 months compared to 18 months for patients who received placebo."